PIMOCARDIN

Benefits:

• Dilates blood vessels, reduces the load on the heart
• Increases the strength of heart contractions
• Improves heart pumping function of the heart
• Improves the quality and longevity of the pet's life
• Suitable for lifelong use

Composition and pharmacological properties.

PIMOCARDIN® is available in three dosages. 1 tablet contains pimobendan - 1.25 mg; 5 mg; 10 mg as active ingredient, as well as lactose, microcrystalline cellulose, pregelatinized corn starch, colloidal silicon dioxide, calcium stearate and an additive with the taste and aroma of fresh meat as excipients.

Pimobendan, which is a component of the drug, is a benzimidazole-pyridazinone derivative and has a positive inotropic and vasodilating (vasodilating) effect. Unlike cardiac glycosides, the positive inotropic effect of pimobendan is due to two mechanisms: increased sensitivity of the fibers (myofibrils) of the heart muscle to calcium and inhibition of phosphodiesterase III (vasodilating effect), thereby providing arterial dilation. Due to the positive inotropic and vasodilating effect, the drug increases the strength of heart contractions and reduces both preload and postload in heart failure in dogs.

After oral administration, pimobendan is rapidly absorbed into the systemic circulation, its bioavailability is 60-63%; blood plasma elimination half-life is 0.4 ± 0.1 hours, and the elimination half-life of its active metabolite is 2.0 ± 0.3 hours. Pimobendan is excreted from the animal body mainly with bile in the form of a metabolite of pimobendan.

Indications

PIMOCARDIN® is prescribed to dogs for the treatment of heart failure caused by dilated cardiomyopathy (DCMP) at the asymptomatic (subclinical) and clinical stages of the disease, as well as in myxomatous degeneration of the bicuspid or tricuspid valve at the clinical stage and myxomatous degeneration of the mitral valve at the asymptomatic (preclinical) stage of the disease.

Contraindications.

The product is contraindicated in cases of individual hypersensitivity of the animal to the components of the drug.

Do not use PIMOCARDIN® in hypertrophic cardiomyopathy and clinical conditions in which cardiac blood output cannot be increased due to functional or anatomical features (for example, aortic stenosis), in severe liver damage, as it is mainly metabolized in the liver.

The drug has not been tested for the treatment of asymptomatic myxomatous mitral heart disease (MMHD) in dogs with severe supraventricular and/or ventricular tachyarrhythmia.

No special safety studies have been conducted with PIMOCARDIN® in pregnant and lactating females. If necessary, the possibility of using PIMOCARDIN® in pregnant and lactating females is determined by the attending physician based on an assessment of the ratio between the expected benefit to the mother and the possible risk to the offspring.

The product is not intended for use in food-producing animals.

Posology and method of administration

PIMOCARDIN® is administered to animals orally 1 hour before feeding. The dose of the drug and treatment duration are determined by a veterinarian, depending on the severity of the disease and the condition of the animal.

Daily dose of pimobendan (active ingredient) ranges from 0.2 mg to 0.6 mg per 1 kg of animal bodyweight divided into two doses. The recommended dose to achieve a clinical effect is 0.5 mg/kg of animal bodyweight per day.

Recommended doses of the drug product, depending on the animal bodyweight, are shown in the table below:

To determine the dose based on the animal bodyweight more accurately, the tablet can be divided into halves.

In congestive heart failure, the drug is used for dogs continuously with individual dose adjustment.

It is recommended to regularly monitor glucose level in dogs with diabetes mellitus.

Do not skip doses, as this may lead to a decrease in therapeutic effect. If you missed the scheduled dose, continue treatment at the same dose and according to the same application scheme.

Side effects.

When used in accordance with these instructions, the product usually does not cause side effects or complications.
In very rare cases, a slight positive chronotropic effect, vomiting, temporary diarrhea, anorexia or lethargy are possible. These effects may be controlled by reducing the drug dose.
Despite the fact that the relationship with pimobendan has not been precisely established, in extremely rare cases during treatment, signs of an effect on primary hemostasis (petechiae on the mucous membrane, subcutaneous bleeding) are possible. These symptoms are not observed after treatment discontinuation.
Specific effects after first administration and withdrawal have not been established.

Overdose.

In case of drug overdose, vomiting, apathy, positive chronotropic effect, ataxia, heart murmurs and hypotension are possible. In this case, discontinue treatment with the product and start symptomatic treatment (for example, activated charcoal) immediately.

Other drug interactions.

When PIMOCARDIN® is co-administered with slow calcium channel blockers (verapamil, diltiazem) and a beta-blocker (propranolol), the effect of pimobendan is reduced. The use of the drug in combination with diuretics or ACE inhibitors has an additional positive therapeutic effect. Data on possible interactions with drugs of other pharmacological groups are lacking.

Storage.

Store the product in a closed manufacturer's package, protected from direct sunlight, at 5°C to 25°C. Keep out of reach of children.

Shelf-life of the product when stored under recommended conditions is 3 years from the date of manufacture; after blister opening the product can be stored under recommended conditions for no longer than 3 months. Do not use after the expiry date.

Dosage form.

5 blisters of 10 tablets, instructions for use.

Outer packaging: carton.